• 1
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 21372150.
  • 2
    Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tobacco Control. 2006; 15: 345347.
  • 3
    The International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT scanning. N Engl J Med. 2006; 355: 17631771.
  • 4
    Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. NEngl J Med. 2005; 353: 17841792.
  • 5
    Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with resected non-small cell lung cancer. N Engl J Med. 2004; 350: 351360.
  • 6
    Winston T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med. 2005; 352: 25892597.
  • 7
    Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006; 7: 719727.
  • 8
    Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350: 17131721.
  • 9
    Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol. 2006; 24(18 suppl ): 366S. Abstract 7008.
  • 10
    Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2006; 24(18 suppl ): 365S. Abstract 7007.
  • 11
    Fry WA, Philips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999; 86: 18671876.
  • 12
    Cancer Reporting in California. Volume 1: Abstracting and Coding Procedures for Hospitals. Emeryville, Calif: California Tumor Registry, Department of Health Services, Cancer Surveillance Section; 1986.
  • 13
    Zell JA, Ou S-HI, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol. 2005; 23: 83968405.
  • 14
    Zell JA, Ou S-HI, Ziogas A, et al. Long-term survival difference for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol. 2006; 17: 12551262.
  • 15
    Parikh-Patel A, Bates JH, Campleman S. Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988–2000. Cancer. 2006; 107(5 suppl ): 11891195.
  • 16
    Sun Z, Aubry M-C, Deschamps C, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovascular Surg. 2006; 131: 10141020.
  • 17
    Iwasaki A, Shirakusa T, Enatsu S, et al. Is T2 non-small cell lung cancer located in left lower lobe appropriate to upstage? Interact Cardiovasc Thorac Surg. 2005; 4: 126129.
  • 18
    Jones DR, Daniel TM, Denlinger CE, et al. Stage IB nonsmall cell lung cancers: are they all the same? Ann Thorac Surg. 2006; 81: 19581962.
  • 19
    Ichinose Y, Kato H, Koike T, et al. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg. 2001; 122: 803808.
  • 20
    Kotoulas CS, Foroulis CN, Kostikas K, et al. Involvement of lymphatic metastasis spread in non-small cell lung cancer according to the primary cancer location. Lung Cancer. 2004; 44: 183191.
  • 21
    Cerfolio RJ, Bryant AS. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall cell lung cancer. Ann Thorac Surg. 2006; 81: 19691973.
  • 22
    Rocha AT, McCormack M, Montana G, et al. Association between lower lobe location and upstaging for early-stage non-small cell lung cancer. Chest. 2004; 125: 14241430.
  • 23
    Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Ann Thorac Surg. 2000; 70: 358366.
  • 24
    Passlick B. Initial surgical staging of lung cancer. Lung Cancer. 2003; 42: S21S25.
  • 25
    Gajra A, Newman N, Gamble GP, et al. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol. 2003; 21: 10291034.
  • 26
    Wu Y, Lin C, Hsu W, et al. Long term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg. 2003; 24: 9941001.
  • 27
    Ludwig MS, Goodman M, Miller DL, et al. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest. 2005; 128: 15451550.
  • 28
    Doddoli C, Aragon A, Barlesi F, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small cell lung cancer? Eur J Cardiothorac Surg. 2005: 27: 680685.
  • 29
    Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg. 1995; 60: 615623.
  • 30
    Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the new intergroup trial. Clin Lung Cancer. 2006; 8: 1821.
  • 31
    Wisnivesky JP, Yankelvitz D, Henschke CI. The effect of tumor size on curability of stage I non-small cell lung cancer. Chest. 2004; 126: 761765.
  • 32
    Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006; 118: 257262.
  • 33
    Liu W, Innicenti F, Chen P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 2003; 9: 10091012.
  • 34
    Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol. 2006; 1: 406412.
  • 35
    Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006; 355: 570580.
  • 36
    Chen H-Y, Yu S-L, Chen C-H, et al. A five-gene signature and clinical outcome in non-small cell lung cancer. N Engl J Med. 2007; 356: 1120.